MS Speaks
Multiple Sclerosis => TREATMENTS => OCREVUS (ocrelizumab) => Topic started by: agate on April 06, 2018, 06:37:14 am
-
In the UK, NICE (National Institute for Health and Care Excellence) is the organization that decides whether there will be National Health Service funding for a new drug. They've decided that Ocrevus isn't cost-effective enough to warrant use of NHS resources, based on the available evidence. Ocrevus wasn't compared with all of the other available MS drugs--just with interferon beta-1a.
http://www.pharmatimes.com/news/nice_no_for_roches_ocrevus_1230626